Alopecia areata (AA) is an autoimmune condition characterized by non-scarring hair loss on the scalp, face, and body, affecting approximately 2% of the global population. Current treatments, including topical corticosteroids, topical immunotherapies, and systemic immunosuppressants, often demonstrate inconsistent efficacy and raise concerns about long-term safety, emphasizing the need for safer and more effective therapies. Janus kinase (JAK) inhibitors have emerged as a promising treatment option, offering a targeted approach by addressing the immune-mediated mechanisms driving hair follicle destruction in AA. Recent clinical advances have led to FDA approval of three JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—based on pivotal trials showing significant hair regrowth. Baricitinib has demonstrated durable efficacy, with 35–40% of patients achieving a Severity of Alopecia Tool (SALT) score ≤ 20 at 36 weeks. Ritlecitinib similarly reported 23% of patients achieving a SALT score ≤ 20 at week 24. Deuruxolitinib has also shown efficacy with 31% of patients achieving a SALT score ≤ 20 at 24 weeks. Off-label use of JAK inhibitors like tofacitinib and ruxolitinib have also demonstrated efficacy in limited studies. This review aims to consolidate and summarize the latest clinical evidence and trial data on JAK inhibitors for AA, providing an up-to-date resource for clinicians and researchers to guide evidence-based management and optimize therapeutic outcomes. Alopecia areata is a condition where a person's immune system, which normally protects the body, mistakenly attacks their own hair. This causes hair to fall out on the head, face, or even all over the body. Treatments including different creams, steroid shots, or pills that dampen the immune system are used to help with hair regrowth, but these therapies can have serious side effects. Janus kinase inhibitors are being increasingly used in dermatology to help treat people with alopecia areata. These medications work by calming down the part of the immune system that is attacking the hair. Three Janus kinase inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—have been approved by the United States Food and Drug Administration. In clinical trials, many people who took these medications grew back a significant amount of their hair within several months. Some Janus kinase inhibitors that have been approved for other conditions, like tofacitinib and ruxolitinib, have also shown promise in treating alopecia areata. As other medications in this drug class are being tested in clinical trials, new data continue to emerge. This review outlines the unique features of each Janus kinase inhibitor, including how they work, how they are processed in the body, and the results of major clinical trials.
Sanchez et al. (Tue,) studied this question.